On April 24, 2024 MorphoSys AG (FSE: MOR; NASDAQ: MOR) reported that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be highlighted during an oral presentation on Friday, May 31, at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, MorphoSys, APR 24, 2024, View Source [SID1234642300]). The congress is being held in Chicago, Illinois, from May 31 to June 4, 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additionally, new data from the Phase 2 study of tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, in patients with advanced solid tumors or hematologic malignancies will be showcased in a poster presentation at ASCO (Free ASCO Whitepaper) 2024.
ASCO 2024 Presentation Details
Abstract Title
Abstract Number Date/Time
Pelabresib
ORAL
Updated Safety and Efficacy Data from the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis #6502 Friday, May 31, 2:45 – 5:45 p.m. CDT / Friday, May 31, 9:45 p.m. – Saturday, June 1, 12:45 a.m. CEST
Presentation Time: 3:09 – 3:21 p.m. CDT / 10:09 – 10:21 p.m. CEST
Tulmimetostat
POSTER
Phase II Dose Optimization with EZH2/EZH1 Inhibitor Tulmimetostat in Patients (pts) with Advanced Solid Tumors or Hematologic Malignancies
#3097 Saturday, June 1, 9:00 a.m. – 12:00 p.m. CDT / 4:00 p.m. – 7:00 p.m. CEST
The full text of each abstract will be available on May 23 at 4:00 p.m. CDT. Please refer to the ASCO (Free ASCO Whitepaper) 2024 online program for full session details and data presentation listings.